Improving Patient-centered Care for Diabetes in Bangladesh Through "Dynamic Integration" of Vision Care on the Demand Side
Launched by ORBIS · May 12, 2025
Trial Information
Current as of July 06, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to improve care for people with diabetes and related eye problems, specifically diabetic retinopathy, in Bangladesh. The researchers want to see if sending automated voice messages to remind patients about their check-ups can help them keep their appointments and understand the importance of managing their diabetes to prevent vision loss. They will also look at whether this approach is cost-effective, meaning if it is worth the money spent to help more patients get the care they need.
To join the study, participants must be over 30 years old, have been diagnosed with diabetes in the last six months, and have high-risk diabetic retinopathy. They also need to be treated at Dinajpur Diabetes Hospital and have a mobile phone to receive the voice messages. If someone chooses to participate, they can expect to receive helpful reminders about their appointments and free reading glasses. This trial is not yet recruiting participants, but it aims to make diabetes care more accessible and effective for those who need it.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed with DM within the last 6 months
- • Diagnosed with high-risk DR
- • Over 30 years of age
- • Currently treated at the Dinajpur Diabetes Hospital
- • Possess a mobile phone to receive voice messages
- • Willingness to participate in the study
- Exclusion Criteria:
- • Other significant causes of vision loss
- • Medical conditions that could impair compliance with follow-up (such as stroke, dementia, etc.)
- • Do not possess a mobile phone to receive voice messages
- • Not willing to participate in the study
About Orbis
Orbis is a leading clinical trial sponsor dedicated to advancing medical research and innovation through robust and ethically conducted clinical studies. With a focus on enhancing patient care and treatment options across various therapeutic areas, Orbis collaborates with healthcare professionals, institutions, and regulatory bodies to ensure the integrity and reliability of trial outcomes. Committed to fostering transparency and scientific rigor, Orbis aims to accelerate the development of new therapies while prioritizing patient safety and well-being.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dinajpur Sadar, , Bangladesh
Dinajpur, , Bangladesh
Patients applied
Trial Officials
Munir Ahmed
Principal Investigator
Orbis Bangladesh
Nathan Congdon
Principal Investigator
Orbis
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported